What Are Peptides?

Peptides are short chains of amino acids (typically 2–50 amino acids) linked by peptide bonds — the same type of covalent bond that holds proteins together. Each peptide has an amino-terminal (N-terminus) and a carboxy-terminal (C-terminus) end, and the amino acid sequence determines its structure and function.

The human body naturally produces hundreds of peptides that function as hormones, neurotransmitters, growth factors, and antimicrobial agents. Examples of endogenous peptides include insulin (51 amino acids), enkephalins (5 amino acids), and oxytocin (9 amino acids).

The peptide bond forms through a condensation reaction between the carboxyl group (-COOH) of one amino acid and the amino group (-NH₂) of the next, releasing a water molecule. Secondary structure (α-helices, β-pleated sheets) and tertiary folding determine each peptide's biological activity.

Peptides act primarily by binding to specific cell surface receptors (GPCRs, tyrosine kinase receptors) or, less commonly, through intracellular mechanisms. Upon receptor binding, intracellular signaling pathways (e.g., cAMP, MAPK, PI3K/Akt) are activated, translating into a biological response.

Unlike steroids, peptides do not easily cross the cell membrane due to their hydrophilic nature. This means their action depends largely on the presence of appropriate receptors in the target tissue, theoretically offering greater specificity but also susceptibility to degradation.

Peptides are functionally classified by their primary mechanism of action and biological target:

It is critical to distinguish peptides that have completed clinical trials and received regulatory approval (FDA, EMA) from those that remain at investigational or preclinical stage.

⚠️ A peptide's regulatory status does not automatically imply efficacy or safety. Even approved peptides are used under medical supervision for specific indications.

The route of administration critically affects bioavailability, half-life, and efficacy of a peptide. The choice depends on molecular weight, stability, and target tissue.

Peptides are inherently unstable molecules — vulnerable to enzymatic degradation (proteases), thermal denaturation, oxidation, and hydrolysis. This is why the majority of peptides:

• •Are available in lyophilized (freeze-dried) form for long-term stability
• •Require reconstitution with bacteriostatic water before use
• •Must be refrigerated (2–8°C) after reconstitution
• •Have limited shelf life after reconstitution (typically 14–28 days)
• •Are subject to photodegradation — must be protected from light

The pharmaceutical industry addresses these challenges through chemical modifications (PEGylation, D-amino acids, cyclization, fatty acid chains) that increase half-life. Semaglutide, for example, uses a C-18 fatty acid linkage to achieve once-weekly dosing.

The regulatory status of peptides varies significantly between countries and regions. In the US, the FDA regulates peptides as pharmaceutical products. In the EU, the EMA follows a similar approach. Russia (EAEU) has approved certain peptides (e.g., Semax, Selank) that lack Western approval.

• •FDA/EMA approved: Semaglutide, Tirzepatide, Liraglutide, Bremelanotide, Tesamorelin, Desmopressin
• •Approved in Russia/EAEU only: Semax, Selank, Thymalin, Khavinson peptides
• •Research (no approval anywhere): BPC-157, TB-500, Epithalon, MOTS-c, GHK-Cu
• •The FDA categorizes many unapproved peptides as Category 2 compounds — permitted for research use only

EU legislation regarding research chemicals pertains to use within a research framework. The purchase, possession, or use of peptides is subject to the local regulations of each member state.

The quality of research evidence varies enormously between peptides. Understanding the evidence hierarchy is essential:

• •Check whether data comes from human or animal studies
• •Look for peer-reviewed publications, not marketing material
• •Note sample size — studies with <20 participants are very small
• •Check whether findings have been replicated by independent teams
• •Look for potential conflicts of interest

The majority of peptides have not received regulatory approval for clinical use. This means human safety data is often limited or nonexistent.

• •No long-term safety data exists for most research peptides
• •Drug interactions have not been fully studied
• •Quality and purity of research peptides are not regulated like pharmaceuticals
• •Special populations (pregnant, children, immunocompromised) are generally contraindicated
• •Self-administration without medical supervision carries risks

The information on this page comes from published literature and does not constitute medical advice. Always consult a healthcare professional before any decision.